NGLY1 Deficiency PerlQuest
“We’ve worked closely with the Perlara team since the company’s formation. We are proud to be a launch partner of PerlQuests and are excited about the drug leads that will emerge. Perlara’s nimble platform allows it to quickly iterate and in turn cut down the time when NGLY1 patients can receive a life-saving treatment.”
Matt Wilsey
President of Grace Science Foundation
President of Grace Science Foundation